[ad_1]
Original Title: Let Ordinary People Afford the Debut of Domestically Made New Corona Inactivated Vaccine at the Service Fair
Beijing Commercial Daily News (Reporter Tao Feng Liu Hanlin) On September 6, the reporter went to the booth of Sinopharm China Biotechnology Co., Ltd. (hereinafter “China Bio”) in the public health and epidemic prevention zone . The exhibition area booth displayed the new corona virus nucleic acid molecular detection reagent and the new coronavirus inactivated vaccine developed by the Sinopharm Group, and the two new coronavirus inactivated vaccines it carried out attracted many visitors. from the service fair to stop and observe.
It is understood that as a research company for the two new corona inactivated vaccines mentioned above, China Biotechnology has a 100-year history and is a research and production company focused on biopharmaceuticals. “During this new corona epidemic, the entire group could be diagnosed, treatable and preventable,” Zhang Yinan, deputy director general of the China Biological Marketing Center, told a reporter for the Beijing Business Daily.
“What can be prevented? It is to prevent healthy people from getting the new crown due to the epidemic,” said Zhang Yinan. On April 12, Sino Biotech reportedly became the first company in the world to gain clinical approval for inactivated vaccines in China. So far, the products of his two companies have entered clinical trials. The two new corona vaccines showcased this time are from the Wuhan Institute of Biologicals and the Beijing Institute of Biologicals.
After the first and second phase of the vaccine clinical trials were completed in Henan, the vaccine has now entered the third phase of clinical trials, and the scope of this trial is focused on global epidemic areas. These include the United Arab Emirates, Paris, Peru, Morocco, Argentina and Jordan and other countries and regions.
Zhang Yinan said that the two aforementioned research institutes have taken the lead in the world to build the “arsenal” of the new corona inactivated vaccine. Among them, the P3 laboratory in the workshop has also obtained national biosafety certification, with an annual production capacity of up to 300 million doses, allowing more people to become aware of the availability of vaccines.
According to reports, since the emergency use of the new corona vaccine was officially launched in China on July 22, the new inactivated corona vaccine made by Sinopharm China Biotech has also been approved for emergency use first. Wuhan Biological Products Institute and Beijing Biological Products Research Institute The safety and efficacy of the two vaccines are ahead of the world.
It is worth mentioning that in an interview on the same day, Zhou Song, China’s general counsel for biological law, said that the results of the third phase of clinical trials will be released before the end of the year. After subsequent approval procedures, the new domestically made corona inactivated vaccine is expected to be on the market by the end of the year. “What is clear at the moment is that our vaccine will greatly alleviate market demand once it is released. What can be guaranteed is that people can use it and pay for it.”
